3-(2-bromophenyl)-2-oxopropanoic acid | 120240-65-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(2-bromophenyl)-2-oxopropanoic acid
• 英文别名: 3-(2-bromophenyl)-2-oxopropionic acid
• CAS: 120240-65-5
• 化学式: C₉H₇BrO₃
• 分子量: 243.057
• InChiKey: LPTGSFCWLPDCIT-UHFFFAOYSA-N

物化性质

• 熔点：
  160-162 °C
• 沸点：
  356.3±25.0 °C(Predicted)
• 密度：
  1.656±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(2-bromophenyl)-2-oxopropanoic acid 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 4-氨基-2-甲巯基嘧啶-5-甲醛 在 乙酸乙酯 、 氯仿 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.67h， 以2.786 g of the title product were thus obtained的产率得到6-(2-bromo-phenyl)-2-methylsulfanyl-pyrido[2,3-d]pyrimidine-7-carboxylic acid
  参考文献：
  名称：

  Pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents

  摘要：

  本发明描述了一般式化合物I的制备方法，含有它们的药物及其制备方法，以及这些化合物作为药物活性剂的用途。该化合物表现出蛋白激酶抑制剂的活性，特别是src家族酪氨酸激酶抑制剂，因此可用于治疗由这些酪氨酸激酶介导的疾病。

  公开号：

  US20050130984A1

文献信息

• A new type of chiral-pyridoxamines for catalytic asymmetric transamination of α-keto acids
  作者：Jianfeng Chen、Junyu Zhao、Xing Gong、Dongfang Xu、Baoguo Zhao

  DOI：10.1016/j.tetlet.2016.09.005

  日期：2016.10

  A new type of chiral pyridoxamines bearing an adjacent chiral stereocenter has been developed via multi-step synthesis. The pyridoxamines displayed catalytic activity in asymmetric transamination of α-keto acids to give a variety of optically active amino acids in 27–78% yields with 34–62% ee’s under very mild conditions. This work provides a synthetic strategy to construct new chiral pyridoxamines

  通过多步合成已经开发了一种新型的带有相邻手性立体中心的手性吡ido胺。吡ido胺在非常温和的条件下，在α-酮酸的不对称转氨反应中显示出催化活性，从而以27-78％的产率提供了34-62％ee的多种光学活性氨基酸。这项工作提供了使用溴吡啶7作为关键合成子来构建新的手性吡ido胺的合成策略，也代表了手性吡x胺在不对称催化中的早期应用实例。
• [EN] ANTIDIABETIC ENOLIC GLUCOSIDE OF PHENYLPYRUVIC ACID<br/>[FR] GLUCOSIDE ÉNOLIQUE DE L'ACIDE PHÉNYLPYRUVIQUE À PROPRIÉTÉS ANTIDIABÉTIQUES
  申请人：ZADEC APS

  公开号：WO2012045363A1

  公开（公告）日：2012-04-12

  There is provided an antidiabetic enolic glucoside of phenylpyruvic acid and derivatives thereof for use as medicaments, especially normoglycemic agents, i.e. for lowering blood glucose levels to normal levels in mammals that are obese, pre-diabetic or have diabetes, obesity and/or syndrome X.Hence the compounds of the present invention help to manage blood sugar levels, i.e. helping the body by balancing the blood sugar levels; helping to keep balanced blood glucose levels, particularly in humans with diabetes; aiding by enhancing the glucose uptake by the cells and by reducing sugar levels, thus improving or restoring the glucose tolerance; optimizing the glycemic response; normalizing the glucose tolerance.

  提供了一种抗糖尿病的苯丙酮酸烯醇葡萄糖苷及其衍生物，用作药物，特别是用作正常血糖代理，即降低哺乳动物（肥胖、糖尿病前期或患有糖尿病、肥胖和/或综合征X）的血糖水平至正常水平。因此，本发明的化合物有助于管理血糖水平，即通过平衡血糖水平来帮助身体；帮助保持平衡的血糖水平，特别是在患有糖尿病的人类中；通过增强细胞对葡萄糖的摄取和降低糖分水平来帮助，从而改善或恢复葡萄糖耐量；优化血糖反应；正常化葡萄糖耐量。
• ANTIDIABETIC ENOLIC GLUCOSIDE OF PHENYLPYRUVIC ACID
  申请人：Joubert Elizabeth

  公开号：US20130310331A1

  公开（公告）日：2013-11-21

  There is provided an antidiabetic enolic glucoside of phenylpyruvic acid and derivatives thereof for use as medicaments, especially normoglycemic agents, i.e. for lowering blood glucose levels to normal levels in mammals that are obese, pre-diabetic or have diabetes, obesity and/or syndrome X. Hence the compounds of the present invention help to manage blood sugar levels, i.e. helping the body by balancing the blood sugar levels; helping to keep balanced blood glucose levels, particularly in humans with diabetes; aiding by enhancing the glucose uptake by the cells and by reducing sugar levels, thus improving or restoring the glucose tolerance; optimizing the glycemic response; normalizing the glucose tolerance.

  提供了一种苯丙酮酸和其衍生物的抗糖尿病烯醇葡萄糖苷，用作药物，特别是用作正常血糖代理，即降低哺乳动物（肥胖、糖尿病前期或有糖尿病、肥胖和/或X综合症）的血糖水平至正常水平。因此，本发明的化合物有助于管理血糖水平，即通过平衡血糖水平来帮助身体；有助于保持平衡的血糖水平，特别是在患有糖尿病的人类中；通过增强细胞对葡萄糖的摄取并降低糖分水平，从而改善或恢复葡萄糖耐受性；优化糖代谢反应；正常化葡萄糖耐受性。
• Method of treating resistant tumors
  申请人：Wyeth Holdings Corporation

  公开号：US20040121965A1

  公开（公告）日：2004-06-24

  The invention provides a method of treating or inhibiting the growth of or eradicating a tumor in a mammal in need thereof wherein said tumor is resistant to at least one chemotherapeutic agent which method comprises providing to said mammal an effective amount of a compound of Formula II or a pharmaceutically acceptable salt thereof.

  本发明提供了一种治疗或抑制哺乳动物体内对至少一种化疗药物产生耐药性的肿瘤生长或根除肿瘤的方法，该方法包括向该哺乳动物提供有效量的公式II化合物或其药学上可接受的盐。
• AMINO ACID DEHYDROGENASE MUTANT AND APPLICATION THEREOF
  申请人：Asymchem Life Science (Tianjin) Co., Ltd

  公开号：EP3839045A1

  公开（公告）日：2021-06-23

  Provided is an amino acid dehydrogenase mutant. The amino acid sequence of the mutant is obtained by mutating the amino acid sequence shown in SEQ ID NO:1. The mutation includes at least one of the following mutation sites: 64th, 94th, 133rd, 137th, 148th, 168th, 173rd, 183 rd, 191st, 207th, 229th, 248th, 255th and 282nd sites; or the amino acid sequence of the amino acid dehydrogenase mutant is an amino acid sequence having the mutation sites in the mutated amino acid sequence and having a 80% or more homology with the mutated amino acid sequence. The mutant enzyme activity is more than 50 times higher than that of wild amino acid dehydrogenase, and the enzyme specificity is also correspondingly improved.

  本研究提供了一种氨基酸脱氢酶突变体。该突变体的氨基酸序列是通过突变 SEQ ID NO:1 所示的氨基酸序列获得的。该突变包括以下突变位点中的至少一个：第 64、94、133、137、148、168、173、183rd、191、207、229、248、255 和 282 位点；或者氨基酸脱氢酶突变体的氨基酸序列是在突变氨基酸序列中具有突变位点且与突变氨基酸序列具有 80% 或以上同源性的氨基酸序列。突变体的酶活性比野生氨基酸脱氢酶高 50 倍以上，酶的特异性也相应提高。